Journal Publication – Nalburiye Dergisi http://nalburiyedergisi.com/ Tue, 22 Nov 2022 05:06:14 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://nalburiyedergisi.com/wp-content/uploads/2021/07/icon-1.png Journal Publication – Nalburiye Dergisi http://nalburiyedergisi.com/ 32 32 Return on investment of the COVID-19 vaccine https://nalburiyedergisi.com/return-on-investment-of-the-covid-19-vaccine/ Tue, 22 Nov 2022 02:06:22 +0000 https://nalburiyedergisi.com/return-on-investment-of-the-covid-19-vaccine/ About the study: In this decision analytic model study of a citywide initiative, every dollar invested in New York City’s COVID-19 vaccination campaign generated estimated savings of $10.19 in direct and indirect costs of health outcomes that would have been incurred without vaccination. The results of this study suggest that vaccination against COVID-19 in New […]]]>

About the study: In this decision analytic model study of a citywide initiative, every dollar invested in New York City’s COVID-19 vaccination campaign generated estimated savings of $10.19 in direct and indirect costs of health outcomes that would have been incurred without vaccination. The results of this study suggest that vaccination against COVID-19 in New York was associated with a reduction in severe consequences and the avoidance of substantial economic losses.

Authors: Alison P. Galvani, Ph.D., of the Yale School of Public Health in New Haven, Connecticut, is the corresponding author.

To access the study under embargo: Visit our For Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2022.43127)

Editor’s note: Please see the article for more information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers with free access to the full-text article This link will be live at the time of the embargo http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.43127?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=112122

About the JAMA Open Network: JAMA Network Open is the new online-only open access general medical journal of the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health fields. Each article is put online for free from the day of its publication.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

]]>
Graduate Student Journal Article Writing Group – Harry A. Sprague Library https://nalburiyedergisi.com/graduate-student-journal-article-writing-group-harry-a-sprague-library/ Fri, 18 Nov 2022 19:52:41 +0000 https://nalburiyedergisi.com/graduate-student-journal-article-writing-group-harry-a-sprague-library/ November 18, 2022 Posted in: Home Page Features, Unclassified Are you a graduate student working on a journal article for publication? Learn more about the Graduate Student Journal Article Writing Group! This writing group will take place during the spring semester (February 3 – May 5, 2023). Weekly topics will include: where to publish, selecting […]]]>

November 18, 2022

Posted in: Home Page Features, Unclassified

Are you a graduate student working on a journal article for publication? Learn more about the Graduate Student Journal Article Writing Group!

This writing group will take place during the spring semester (February 3 – May 5, 2023). Weekly topics will include: where to publish, selecting a journal, writing your pitch, reviewing the literature, managing citations, and more. Participants can participate asynchronously, although a synchronous weekly meeting is convened. We will use Wendy Laura Belcher’s article Writing Your Journal in Twelve Weeks to guide the discussions and work.

Attend one of the upcoming Zoom information sessions where we’ll discuss program flow, expected time commitment, and answer any other questions you may have. If you wish to register without attending an information session, register for the first meeting. Please contact cwe@montclair.edu with any questions. A limited number of places are available.

Information Session Dates – Please register below

Wednesday, November 30, 12-12:30 p.m.
Tuesday, December 6, 8-8:30 p.m.
Friday, January 20, 12-12:30 p.m.
Monday 30 January, 6-6.30 p.m.

Sponsored by the Center for Writing Excellence and the Harry A. Sprague Library.

]]>
Elon University / Today at Elon / Yanica Faustin publishes an article in the International Journal of Environmental Research and Public Health https://nalburiyedergisi.com/elon-university-today-at-elon-yanica-faustin-publishes-an-article-in-the-international-journal-of-environmental-research-and-public-health/ Mon, 14 Nov 2022 16:25:53 +0000 https://nalburiyedergisi.com/elon-university-today-at-elon-yanica-faustin-publishes-an-article-in-the-international-journal-of-environmental-research-and-public-health/ Faustin, assistant professor in the Department of Public Health Studies, shares research that examines the main causes of racialized disparities in population health. Yanica Faustin, Assistant Professor of Public Health Studies, co-authored a paper titled “Black Nativity and Health Disparities: A Research Paradigm for Understanding the Social Determinants of Health” alongside Mosi Ifatunji of the […]]]>

Faustin, assistant professor in the Department of Public Health Studies, shares research that examines the main causes of racialized disparities in population health.

Yanica Faustin, Assistant Professor of Public Health Studies, co-authored a paper titled “Black Nativity and Health Disparities: A Research Paradigm for Understanding the Social Determinants of Health” alongside Mosi Ifatunji of the University of Wisconsin at Madison, Deshira Wallace from the University of North Carolina at Chapel Hill and Wendy Lee, also from the University of Wisconsin at Madison.

Yanica Faustin, Assistant Professor of Public Health Studies

The article, published in a special issue on “The health of African migrants: the burden, determinants and solutions” in the International Journal of Environmental Research and Public Health, compares the mental and physical health of black people born in the United States United and abroad. populations. The manuscript reviews 208 studies and provides a population-based comparative study, analyzing the pattern of health outcomes between foreign-born blacks and US-born blacks.

“The foreign-born black population in the United States has grown exponentially over the past few decades. and yet research on this population has not kept pace with growth,” Faustin said. “Part of what contributes to this disconnect is the lack of relevant data sources.”

While there is some complexity, particularly around mental health, the general trend seen in the literature is that foreign-born blacks have lower rates of adverse health outcomes than blacks. Blacks born in the United States. Many studies have been unable to explain these differences, illustrating the need for further research into contributing structural mechanisms. This publication also highlighted health outcomes where there is less research that focuses on this in comparing black people, such as cancer research.

Additionally, the study discussed the need for increased data collection and data availability at a nationally representative level for the diverse black population living in the United States.

The publication is available online here.

]]>
No more constraint of publication in a journal for the doctorate. students: UGC https://nalburiyedergisi.com/no-more-constraint-of-publication-in-a-journal-for-the-doctorate-students-ugc/ Sat, 12 Nov 2022 05:32:55 +0000 https://nalburiyedergisi.com/no-more-constraint-of-publication-in-a-journal-for-the-doctorate-students-ugc/ The University Grants Commission (UGC) has eliminated the requirement to publish research articles in peer-reviewed journals before submitting a doctoral thesis (PhD) in the new regulations for doctoral programs. Previously, MPhil (Master of Philosophy) scholars had to present at least one research paper at a conference or seminar, while PhD students had to publish at […]]]>

The University Grants Commission (UGC) has eliminated the requirement to publish research articles in peer-reviewed journals before submitting a doctoral thesis (PhD) in the new regulations for doctoral programs.

Previously, MPhil (Master of Philosophy) scholars had to present at least one research paper at a conference or seminar, while PhD students had to publish at least one research paper in a peer-reviewed journal and do two paper presentations at conferences or seminars before submitting their thesis for consideration.

“Publishing research articles in peer-reviewed journals may no longer be mandatory, but that doesn’t mean PhD students should stop doing it altogether. Focusing on high-quality research will lead to publications in good journals, even if it is This will add value when they apply for employment or post-doctoral opportunities,” said M Jagadesh Kumar, President of UGC.

“We recognize that a one-size-fits-all approach is undesirable by eliminating the mandatory publication requirement. PhD students in computer science, for example, prefer to present their papers at conferences rather than publish them in journals. I strongly urge universities to strengthen the PhD evaluation process and train researchers to publish in peer-reviewed journals, present at conferences and apply for patents where possible,” he said.

(To receive our daily E-paper on WhatsApp, please Click here. To receive it on Telegram, please Click here. We allow the PDF of the document to be shared on WhatsApp and other social media platforms.)


]]>
“Publication in journals before the final doctoral thesis is not essential” https://nalburiyedergisi.com/publication-in-journals-before-the-final-doctoral-thesis-is-not-essential/ Wed, 09 Nov 2022 19:07:09 +0000 https://nalburiyedergisi.com/publication-in-journals-before-the-final-doctoral-thesis-is-not-essential/ Indore (Madhya Pradesh): In the new regulations for granting a doctorate, the University Grants Commission removed the requirement for publications in peer-reviewed journals and the presentation of at least two papers at conferences, which were part of the regulations from the UGC, 2016. Until now, it was compulsory for doctoral students to publish at least […]]]>

Indore (Madhya Pradesh): In the new regulations for granting a doctorate, the University Grants Commission removed the requirement for publications in peer-reviewed journals and the presentation of at least two papers at conferences, which were part of the regulations from the UGC, 2016.

Until now, it was compulsory for doctoral students to publish at least one research article in a peer-reviewed journal and to make two presentations of articles at conferences or seminars before submitting their thesis for judgment. Now, publication of research is no longer mandatory prior to submission of a final doctoral thesis. However, if the quality of research is good, researchers will inevitably opt for publication because it will get the API score when selecting for teaching positions.

“Compulsory publication, as needed earlier, was solely responsible for the mushrooming growth of ‘predatory’ journals in the country,” said Professor Abhay Kumar, Director of DAVV’s School of Electronics.

Students pursuing NEP’s flagship 2020 four-year UG program can apply for admission if they achieve 75% overall and after completing one year of PG. The duration of the doctoral program is limited to a maximum of six years with the possibility of two additional years after re-registration and the maximum duration will be 10 years for female students.

These upper limits of duration also include the time devoted to the completion of coursework.

GATE-qualified applicants can also apply for exemption from entrance tests conducted by a university, in addition to those who obtain the UGC, CSIR, JRF and other scholarships. The entrance exam, however, will be organized only by the respective university. Industry applicants may also register as part-time applicants as provided in the regulations. Adjunct professors who are essentially part-time employees can also serve as co-supervisors, according to the new regulations.

The total number of candidates that a professor, an associate professor and an assistant professor can guide, both as director and as co-director, cannot exceed 8, 6 and 4 respectively.


]]>
F-star Therapeutics Announces Publication of Phase 1 Dose Escalation Trial of FS118 in Patients With Advanced PD-L1 Resistant Cancer in Clinical Cancer Research https://nalburiyedergisi.com/f-star-therapeutics-announces-publication-of-phase-1-dose-escalation-trial-of-fs118-in-patients-with-advanced-pd-l1-resistant-cancer-in-clinical-cancer-research/ Mon, 07 Nov 2022 12:30:00 +0000 https://nalburiyedergisi.com/f-star-therapeutics-announces-publication-of-phase-1-dose-escalation-trial-of-fs118-in-patients-with-advanced-pd-l1-resistant-cancer-in-clinical-cancer-research/ F-star Therapeutics, Inc. – FS118 is well tolerated at all dose levels with no serious adverse events related to FS118 therapy – New mechanism showing an increase in peripheral immune cells and LAG-3 excretion – 54.8% disease control rate in patients resistant to PD-L1 at doses > 1 mg/kg, including partial response in anaplastic thyroid […]]]>

F-star Therapeutics, Inc.

– FS118 is well tolerated at all dose levels with no serious adverse events related to FS118 therapy

– New mechanism showing an increase in peripheral immune cells and LAG-3 excretion

– 54.8% disease control rate in patients resistant to PD-L1 at doses > 1 mg/kg, including partial response in anaplastic thyroid cancer

– Other ongoing studies in acquired resistance squamous cell carcinoma of the head and neck and naïve non-small cell lung cancer and diffuse B-cell lymphoma

CAMBRIDGE, U.K. and CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) — F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a pioneering biopharmaceutical company bispecific antibodies for immunotherapy so that more people with cancer can live longer and better lives, today announced the publication of safety and efficacy results from the Phase 1 trial of FS118 in patients with advanced cancer resistant to PD-L1 in Clinical cancer researcha journal of the American Association for Cancer Research.

“Phase 1 data published in Clinical cancer research demonstrate that FS118 has the potential to overcome cancer immune resistance given the prolonged pharmacodynamic activity,” said Louis Kayitalire, Chief Medical Officer of F-star. “We are delighted to see that FS118 was well tolerated, and in this population of heavily pretreated patients with acquired PD-L1 resistance, a partial response was achieved and a disease control rate of 54.8% . We look forward to generating additional data and leveraging our bispecific approach to deliver therapies to patients with advanced cancer. »

FS118 is a first-in-class tetravalent bispecific antibody that binds to LAG-3 and PD-L1, resulting in reversal of immune suppression. The Phase 1 trial is the first-in-human study of FS118 that is evaluating forty-three patients with locally advanced/metastatic cancer with a median of three prior treatments and at least one anti-PD-L1 therapy. Patients received intravenous monotherapy of FS118 weekly with an accelerated dose titration design (800 µg to 0.3 mg/kg) followed by a 3+3 escalating dose extension (1 mg/kg to 20 mg/ kg). Weekly dosing was well tolerated with no dose limiting toxicity (DLT) and no serious adverse event (SEA) related to FS118. The recommended phase 2 dose of FS118 has been established at 10 mg/kg per week. Pharmacodynamic activity was prolonged throughout administration, as demonstrated by increased and sustained levels of soluble LAG-3 and peripheral effector cells. A disease control rate (DCR) of 54.8% was observed in patients receiving 1 mg/kg or more who had acquired resistance to PD-L1-targeted therapy.

The article is titled “A First-in-Human Phase 1 Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in PD-L1-Resistant Advanced Cancer Patients.” and is available online at https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-22-1449/710483/A-Phase-1-first-in-human-study-of-FS118-a. The publication’s lead author was Timothy A. Yap of the University of Texas MD Anderson Cancer Center.

About FS118

F-star’s FS118 is a dual checkpoint inhibitor targeting PD-L1 and LAG-3 that results in LAG-3 excretion and receptor downregulation, via bispecific activity. It is one of a range of dual-antagonist bispecific formats that are being explored in clinical development, each with the potential to elicit a unique biological activity that may result in different clinical outcomes. The unique pharmacology of FS118 potentially offers a longer lasting response in patients. In the Phase 1 clinical trial, FS118 was well tolerated with no serious treatment-related adverse events and no dose-limiting toxicity up to 20 mg/kg.

About F-star Therapeutics, Inc.:

F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering bispecific immunotherapy so that more people with cancer can live longer and live better. F-star is committed to working towards a future free of cancer and other serious diseases, through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. The company has four second-generation immuno-oncology therapies in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property heritage. F-star has over 500 issued patents and pending patent applications relating to its platform technology and product pipeline. The company has attracted several biopharmaceutical partnerships targeting significant unmet needs in several therapeutic areas, including oncology, immunology and CNS. For more information, visit our website and follow us on LinkedIn and Twitter.

Additional information and where to find it:

This communication is neither a recommendation nor an offer to buy or a solicitation of an offer to sell shares of F-star common stock or any other securities. On July 7, 2022, Sino Biopharmaceutical Limited, invoX Biopharm Limited and its direct subsidiary Fennec Acquisition Incorporated filed with the SEC a statement of tender offer on Schedule TO, including an offer to purchase, a letter of and other related documents, and on July 7, 2022, F-star filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC. The offer to purchase common shares of F-star is made only pursuant to the offer to purchase, the letter of transmittal and other related documents filed as part of the schedule TO. INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ BOTH THE PUBLIC OFFER STATEMENT AND THE SOLICITATION/RECOMMENDATION STATEMENT REGARDING THE OFFER, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME BECAUSE THEY CONTAIN IMPORTANT INFORMATION WHAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE OFFERING OF THEIR COMMON SHARES, INCLUDING THE TERMS AND CONDITIONS OF THE PUBLIC OFFER. Investors and security holders may obtain a free copy of these statements and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to information agent for the tender offer, which is Innisfree M&A Incorporated. Investors may also obtain, free of charge, documents filed or provided to the SEC by F-star in the “SEC Filings” section of F-star’s website at https://investors.f-star.com /.

Forward-looking statements:

Certain statements contained in this communication relating to matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as PSLRA. . These include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including regarding the expected timing of our transaction with invoX Pharma. You are warned not to place undue reliance on it. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. F-star undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In some cases, you can identify forward-looking statements by words such as “expects”, “believes”, “plans”, “anticipates”, “projects”, “future”, “intends”, ” may”, “shall”, “should”, “could”, “estimate”, “predict”, “potential”, “continue”, “guidance” or the negative form of these terms or other comparable terms, which refer to to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on our expectations and involve risks and uncertainties; therefore, actual results may differ materially from those expressed or implied by the statements due to a number of factors, including, but not limited to, the satisfaction of the conditions to closing of the proposed transaction, including, but not limited to, obtaining regulatory approvals, the risk of litigation and/or related actions regarding the proposed transaction, F-star’s cash balances, the ability of F -star to remain listed on the Nasdaq capital market, F-star’s status as a clinical-stage immuno-oncologist company and its need for substantial additional funding in order to complete the development and commercialization of its products candidates, which F-star may experience delays in completing, or ultimately be unable to complete, the development and commercialization of its product candidates, which F-star’s clinical trials may not demonstrate adequately the safety and efficacy of its product candidates, that the preclinical development of the drugs is uncertain and that some of F-star’s product candidates may never proceed to clinical trials, that the results of preclinical studies and early clinical trials may not be predictive of the results of later clinical trials, that F-star relies on patents and other intellectual property rights to protect its product candidates, and the enforcement, defense and maintenance of such rights can be difficult and expensive, and that F-star faces significant competition in its drug discovery and development efforts.

New factors appear from time to time and it is not possible for us to predict all of these factors, or to assess the impact of each of these factors on the business or the extent to which any one factor, or combination of factors , can lead to actual results. differ materially from those contained in the forward-looking statements. These risks are discussed in more detail in F-star’s annual report on Form 10-K, quarterly reports on Form 10-Q and other filings from time to time with the SEC. The forward-looking statements included in this communication are based on information available to F-star as of the date of this communication. F-star undertakes no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

For more information, please contact:

For investor inquiries:

John Fraunces

Relationship Manager, Life Sciences Advisors

+1 917-355-2395

jfraunces@lifesciadvisors.com

]]>
Mercator MedSystems Announces Release of Results From Phase 2 TANGO Clinical Trial to Improve Outcomes After Below Knee Arterial Revascularization https://nalburiyedergisi.com/mercator-medsystems-announces-release-of-results-from-phase-2-tango-clinical-trial-to-improve-outcomes-after-below-knee-arterial-revascularization/ Thu, 03 Nov 2022 19:15:00 +0000 https://nalburiyedergisi.com/mercator-medsystems-announces-release-of-results-from-phase-2-tango-clinical-trial-to-improve-outcomes-after-below-knee-arterial-revascularization/ First double-blind randomized controlled trial in the United States to date of unmet need in critical limb ischemia SAN LEANDRO, Calif. /ACCESSWIRE/November 3, 2022/ Mercator MedSystems, Inc. (“Mercator”), a medical technology company specializing in local drug delivery, today announced that data from the Phase 2 TANGO (Temsirolimus adventitial delivery to Improve ANGiographic Outcomes below the […]]]>

First double-blind randomized controlled trial in the United States to date of unmet need in critical limb ischemia

SAN LEANDRO, Calif. /ACCESSWIRE/November 3, 2022/ Mercator MedSystems, Inc. (“Mercator”), a medical technology company specializing in local drug delivery, today announced that data from the Phase 2 TANGO (Temsirolimus adventitial delivery to Improve ANGiographic Outcomes below the knee) have been published in the Journal of Endovascular Therapy (https://doi.org/10.1177/15266028221131459). The trial investigated local administration of a rapamycin analog (temsirolimus) to tissues around arteries with the aim of reducing symptomatic re-obstruction of atherosclerotic arteries below the knee after catheter procedures were used to open the vessels and restore blood flow to the foot. The drug was delivered through Mercator’s Bullfrog micro-infusion device, an FDA-approved product with a microscopic sheathed needle design that, upon inflation of a balloon at the end of the device, drags the micro -needle through the blood vessel wall to deposit the drug into the adventitia, a biologically rich tissue where active cells are known to spread during the process of vessel healing.

In patients with lower leg atherosclerosis, catheter-based procedures to restore blood flow typically involve balloon angioplasty, which opens the artery by displacing obstructions using a high-pressure balloon , or an atherectomy, which physically alters the obstructions by laser, micro-cutters, or micro-grinding surfaces. However, approximately half of these treatment results are not long-lasting, with pain or other symptoms due to reobstruction returning within 6 months of mechanical intervention. Durability of interventional procedures remains a great unmet need in critical limb ischemia and especially for below-knee interventions.

Results from the TANGO clinical trial were positive, as measured by failure of the clinically relevant target lesion, composite of symptomatic reobstruction, or need for an additional procedure to reopen the artery within the first 6 months after the procedure initial. This failure rate was reduced by a relative percentage of 51.3% between trial participants receiving a sham injection of placebo and those receiving the active drug. A measurement of side-view open artery area by x-ray also demonstrated beneficial trends 6 months after the initial procedure, in which the amount of arterial side-view area lost in the first 6 months was 37, 3% lower, relatively, in treatment patients compared to controls. Importantly, this was the first trial of local drug treatment for small arteries below the knee in the United States to report positive double-blind, randomized, controlled data. The use of double-blinding in clinical trials is important to eliminate biases inherent in the analysis of patient outcomes and is used to increase the robustness of clinical signals.

Ken Ouriel, MD, MBA, the manuscript’s corresponding author and NAMSA/Syntactx Medical Director, noted, “The TANGO trial represents significant Level 1 evidence supporting the efficacy of drug delivery in stenotic arteries. and occluded – lesions that have historically been difficult to treat and maintain long-term patency. The efficiency with which the drug was delivered into the vessel wall in this study is a likely factor in the greater success observed compared to other technologies. I’m excited to see this technology continue through testing towards eventual regulatory approval.”

The TANGO study was designed and funded by Mercator, with additional funding from grants provided by the National Heart, Lung, and Blood Institute of the National Institutes of Health. Kirk Seward, PhD, President and Chief Science and Technology Officer of Mercator and Principal Investigator of the NIH grant, added, “The release of this data is an important milestone for Mercator as we continue our efforts to optimize treatment strategies for patients. suffering from debilitating pain and ischemia in their legs As we move this program forward into a Phase 3 trial and seek FDA approvals, we have positive data to inform our decisions and guide our research design We look forward to the potential ability to help many more patients down the road.”

The research reported in the publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number R44HL102998. The content is the sole responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About the Bullfrog® Micro-Infusion Device

The Bullfrog micro-infusion device is FDA cleared and CE marked. The device includes a balloon that hydraulically deploys a microneedle through the vessel wall into perivascular tissue, where the needle can then effectively infuse drugs or biologics around an artery or vein. Drug delivery through the Bullfrog is monitored with X-ray contrast agents, allowing precision therapy to local tissues with visual feedback to the physician using the device.

About Mercator MedSystems, Inc.

Mercator is a medical technology company focused on the clinical and commercial development of proprietary, FDA-cleared, CE-marked micro-infusion technologies, including the Bullfrog® micro-infusion device for the local delivery of therapeutic products in blood vessels and the Blowfish ® Transbronchial micro-infusion catheter for placement in the airways. Mercator is developing clinical applications in peripheral vascular disease, cancer, hypertension and cardiac regeneration. For more information, please visit www.mercatormed.com.

Corporate Contact:

Trent Reutiman
Chief executive officer
Mercator MedSystems, Inc.
520 McCormick Street
San Leandro, CA 94577
Phone: +1.510.564.7757
Email: info@mercatormed.com

THE SOURCE: Mercator MedSystems

See the source version on accesswire.com:
https://www.accesswire.com/723833/Mercator-MedSystems-Announces-Publication-of-Results-from-TANGO-Phase-2-Clinical-Trial-to-Improve-Outcomes-after-Below-Knee-Arterial- Revascularization

]]>
Prominent journal publishes COVID-19 research compiled by biology professor and students https://nalburiyedergisi.com/prominent-journal-publishes-covid-19-research-compiled-by-biology-professor-and-students/ Mon, 31 Oct 2022 19:33:01 +0000 https://nalburiyedergisi.com/prominent-journal-publishes-covid-19-research-compiled-by-biology-professor-and-students/ The team consisting of Dr. Emeka Okeke and three students – Joshua Ninan, Caitlin Snyder and Esmeiry Ventura – compiled a research study that examined the role of immune cells in inflammation and mortality in severe cases of COVID- 19. Their study was published in the journal Frontiers in Immunology. The role of immune cells […]]]>

The team consisting of Dr. Emeka Okeke and three students – Joshua Ninan, Caitlin Snyder and Esmeiry Ventura – compiled a research study that examined the role of immune cells in inflammation and mortality in severe cases of COVID- 19. Their study was published in the journal Frontiers in Immunology.

The role of immune cells in driving inflammation and mortality in severe cases of COVID-19 has been the subject of a research study, compiled by Assistant Professor Emeka Okeke of the Department of Biology and three students in Science from SUNY Fredonia, which was published in the prestigious journal Frontiers in Immunology.

The three students are: Joshua Ninan, a graduate of Cattaraugus-Little Valley High School, Cattaraugus; Esmeiry Ventura, senior, majoring in biochemistry, majoring in chemistry, in the pre-med program, graduated from Hicksville High School in Melville; and Caitlin Snyder, junior, majoring in biochemistry and a graduate of Notre Dame High School in Utica.

Frontiers in Immunology is the official journal of the International Union of Immunological Societies.

“Extracellular Neutrophil Traps, Sepsis, and COVID-19 – A Tripod” highlights the role of white blood cells, called neutrophils, in driving inflammation and mortality in severe cases of COVID-19, said the Dr Okeke. “Viruses like SARS-CoV-2 cause neutrophils to release proteins in a cobweb-like fashion, which we call neutrophil extracellular traps (NETs), and this spreads inflammation.”

“About 20% of patients with COVID-19 progress to severe disease and our research highlights the contribution of NETs to severe cases of COVID-19,” Okeke explained. The work is very important because understanding the immunopathology (the disease-associated immune responses) of COVID-19 is essential for the development of effective therapies that will reduce deaths in COVID-19 and end the global pandemic, Okeke said.

The research discusses evidence indicating that severe COVID-19 has clinical presentations consistent with definitions of viral sepsis, a life-threatening condition that occurs when the body’s response to an infection damages its own tissues and can cause system failure. organ and death. The role of neutrophils and NET formation in the pathogenesis – the origin and development of disease – of severe COVID-19 is highlighted in the study.

Ms. Ventura analyzed the role of neutrophils in diseases such as sepsis and COVID-19, researching scientific literature and clinical trials. “I mainly focused on the role of neutrophil extracellular traps (NETs) in sepsis and COVID-19 and targeting of NETs in COVID-19,” Ventura said. “I have researched many different clinical trials of NET inhibitors for the treatment of COVID-19.”

Ventura said this experience helped her grow as an undergraduate student and broaden her knowledge of scientific research. It taught him to take initiative and to be able to work with a small team of other students.

“It makes me happy to be able to share with the world the importance of neutrophils and how it can affect medical complications like autoimmune diseases. Having read many other research papers in preparation for writing this one, I learned a lot of skills,” she said, and I learned to write scientifically.

“I also learned about the process of publishing a research paper,” said Ventura, who plans to become a dermatologist. “Overall, this publication has exposed me to the professional world of scientific research.”

“By researching to find evidence for these NET proteins in severe cases of COVID-19, I learned to navigate credible sources in order to find the information needed.” -Caitlin Snyder

The development of research skills was one of the main lessons of the research study for Snyder.

“It was the first time I’ve been asked to help with a post and I learned a lot,” Snyder said. “By researching to find evidence for these NET proteins in severe cases of COVID-19, I learned to navigate credible sources in order to find the information needed.” Snyder has applied these skills to other articles she writes.

Snyder’s goal after graduation is to attend medical school and become an OBGYN doctor.

Drugs that prevent or inhibit NET formation are potential candidates for the treatment of COVID-19, the study concludes. “As our understanding of the molecular mechanisms of neutrophil extracellular trap formation increases, more therapies targeting neutrophil extracellular traps will become available and may hold promise for the effective treatment of severe COVID-19,” the study suggests.

Further research is needed to understand the behavior of neutrophils during infection with SARS-CoV-2, the cause of the COVID-19 pandemic. Several laboratories around the world are currently testing inhibitors of neutrophil extracellular trapping for the treatment of COVID-19.

Students compiled literature searches and drafted portions of the manuscript. Okeke edited the manuscript before publication. All authors contributed to the article.

This research compiled by students in Okeke’s lab during the summer of 2021 prepared them for further research in graduate school after receiving their undergraduate degrees, Okeke said.

Frontiers in Immunology is available at: Borders | Extracellular neutrophil traps, sepsis and COVID-19 – A tripod.

“My lab is committed to finding new therapies to control the inflammatory response of immune cells,” Okeke said. “We are currently exploring the anti-inflammatory activity of potato-derived proteins.”

A new potato protein with anti-inflammatory activity was recently identified in the lab, Okeke noted, and this finding was recently published in the scientific journal Molecules, a peer-reviewed open-access chemistry journal. Okeke and Ventura were among the authors of the study.

The article published in Molecules can be found at: Molecules | Free Full Text | TNKPVI, a putative bioaccessible pharmacophore of the anti-inflammatory decapeptide derived from potato patatin DIKTNKPVIF

]]>
Dick Wolfsie: These are words that fight https://nalburiyedergisi.com/dick-wolfsie-these-are-words-that-fight/ Sat, 29 Oct 2022 08:00:00 +0000 https://nalburiyedergisi.com/dick-wolfsie-these-are-words-that-fight/ Dick Wolfsie A woman who is silent during an argument with her husband is four times more likely to die of heart disease. That’s according to a study that was published in the Journal of Psychosomatic Medicine, a publication that I don’t usually read, but at my doctor’s office I had a choice between this […]]]>

A woman who is silent during an argument with her husband is four times more likely to die of heart disease. That’s according to a study that was published in the Journal of Psychosomatic Medicine, a publication that I don’t usually read, but at my doctor’s office I had a choice between this or a Reader’s Digest from 1993.

So let me understand this. If I argue with my wife, I’m a rude, sexist bully. But if she wants to argue with me, will she live longer? This suggests that more women will be keen to challenge their husbands’ views in hopes of staying healthy. This puts men in a difficult situation. My favorite phrase to Mary Ellen: “Would it kill you to agree with me to change?” has a new meaning.

That same newspaper also revealed to the public that drinking multiple cups of coffee a day is good for your health, just months after the same publication claimed that coffee caused heart disease. For a long time they also said tea was good for you, so now I drink tea and coffee four times a day just to be sure. I’m not convinced that I will live longer, but since I can never fall asleep, I will definitely feel longer.

My wife and I have argued about weird things over the years. “Arguing” is probably a poor choice of words, because Mary Ellen always reads this weekly column before it’s published and she wouldn’t want readers to assume we don’t get along. We talked about it the other day as our voices grew louder and we clenched our fingers. In the end, I would have said that I had lost the discussion, but now I know that I was simply annihilated in a friendly discussion.

The truth is, we’ve debated just about everything in our 42 years of marriage: how to eat popcorn; when to nap; how to load a dishwasher; how to cook a scrambled egg. Once we debated whether my mother knew how to raise children. I thought my mother had done a good job, but I have to admit that Mary Ellen provided strong evidence to the contrary. Me!

I must not be a good debater because I feel like I’m losing the exchange even though I have most of the facts in my favor. For example, I was sure last July was my wife’s 71st birthday, but she claimed she was only 67. I knew she was joking, but I loved the challenge and the chance to win an argument. I asked to see his passport and driver’s license to strengthen my position. “Not only that, Mary Ellen, but I’m 75 and I remember when we got married I was four years older than you. That hasn’t changed.

“Oh, Dick, you’re living in the past. It was 42 years ago. »

Mary Ellen keeps reminding me that if she digs in and holds her ground in a disagreement, she will live to be old. “Dick, don’t you always want me to be there to take care of you?”

No arguments there.

Retired television personality Dick Wolfsie writes this weekly column for the Daily Journal. Send feedback to [email protected]

]]>
Bidenflation drives up Halloween candy prices https://nalburiyedergisi.com/bidenflation-drives-up-halloween-candy-prices/ Tue, 25 Oct 2022 20:03:48 +0000 https://nalburiyedergisi.com/bidenflation-drives-up-halloween-candy-prices/ Halloween this year will be scary for the wallets of many Americans, as record inflation under the Biden administration has driven the price of candy to record highs. Candy prices are up more than 13% from a year ago, the Labor Department reported, the largest annual increase on record. The price hike is an unfortunate […]]]>

Halloween this year will be scary for the wallets of many Americans, as record inflation under the Biden administration has driven the price of candy to record highs.

Candy prices are up more than 13% from a year ago, the Labor Department reported, the largest annual increase on record. The price hike is an unfortunate moment for the Biden administration less than two weeks before November’s midterm elections, as inflation and the economy remain the top issues for voters.

Overall, Americans’ spending on Halloween is expected to be on par with last year’s record price, the the wall street journal reported:

Halloween shoppers should expect more tricks and fewer treats this year. The average household is expected to spend around $100 on candies, costumes, decorations and related items for this year’s holiday, according to data of the National Retail Federation, a retail trade group. That amount is the second highest the group has ever predicted, only surpassing last year’s record high of $103. In comparison, people spent around $74 on Halloween in 2015.

US candy makers said inflation rates had driven up production costs and the price of ingredients like sugar, flour and milk. The cost of each of these items exceeded the overall rate of consumer inflation in the United States, which rose 8.2% in September from a year ago and approached its highest level in four decades, according to the Labor Department.

President Joe Biden has deflected blame for record US inflation this year. But Democratic House Majority Whip Jim Clyburn (SC) last week admitted “all of us [congressional Democrats] knew that “the president’s $1.9 trillion US bailout package they passed last year would lead to inflation.

]]>